Home Cart Sign in  
Chemical Structure| 1234480-84-2 Chemical Structure| 1234480-84-2

Structure of LRRK2-IN-1
CAS No.: 1234480-84-2

Chemical Structure| 1234480-84-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LRRK2-IN-1 is a potent and selective LRRK2 inhibitor with IC50 values of 6 and 13 nM for G2019S mutant and wild-type LRRK2, respectively.

Synonyms: Leucine-rich repeat kinase 2 IN-1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LRRK2-IN-1

CAS No. :1234480-84-2
Formula : C31H38N8O3
M.W : 570.69
SMILES Code : O=C1N(C)C2=CN=C(NC3=CC=C(C(N4CCC(N5CCN(C)CC5)CC4)=O)C=C3OC)N=C2N(C)C6=CC=CC=C16
Synonyms :
Leucine-rich repeat kinase 2 IN-1
MDL No. :MFCD22683805
InChI Key :IWMCPJZTADUIFX-UHFFFAOYSA-N
Pubchem ID :46843906

Safety of LRRK2-IN-1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • LRRK2

    LRRK2 (WT), IC50:13 nM

    LRRK2 (G2019S), IC50:6 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
AsPC-1 cells 0.5 μM 48 h Inhibited DCLK1 phosphorylation, reduced phospho-DCLK1 levels PMC4030036
HCT116 cells 1.73 μM 48 h Inhibited cell proliferation, significantly reduced cell proliferation PMC4030036
AsPC-1 cells 5 μM 72 h Inhibited cell migration, significantly reduced wound healing PMC4030036
AsPC-1 cells 5 μM 24 h Induced apoptosis, significantly increased Caspase-3/7 activity PMC4030036
THP-1 macrophages 30 nM 1.5 h Inhibited S935 phosphorylation of LRRK2 PMC3526163
SH-SY5Y neuroblastoma cells 100 nM 1.5 h Inhibited S935 phosphorylation of LRRK2 PMC3526163
HT29LGR5+ cells 5.48 μM 72 h Evaluate the effect of LRRK2-IN-1 on cell proliferation, showing a significant decrease in cell viability PMC8243252
ICCACD133+ cells 9.36 μM 72 h Evaluate the effect of LRRK2-IN-1 on cell proliferation, showing a significant decrease in cell viability PMC8243252
PCCALGR5+ cells 4.51 μM 72 h Evaluate the effect of LRRK2-IN-1 on cell proliferation, showing a significant decrease in cell viability PMC8243252
Human Corneal Epithelial Cells (HCECs) 0, 1, 2 μM 12 h LRRK2-IN-1 significantly reduced the expression of inflammatory factors TNF-α, IL-6, and IL-1β in HCECs stimulated with A. fumigatus, indicating that LRRK2-IN-1 effectively suppresses the inflammatory response in HCECs. PMC11804891
HEK293 cells 64 nM To determine the inhibitory effect of LRRK2-IN-1 on LRRK2 kinase activity in HEK293 cells, with an IC50 value of 64 nM. PMC4119403
H4 neuroglioma cells 5 µM 72 h To evaluate the impact of LRRK2 kinase activity inhibition on GCase activity, results showed no significant alteration in GCase activity after 72h inhibition, but GBA and LC3-II protein levels were significantly increased. PMC9266636
H4 neuroglioma cells 5 µM 24 h To evaluate the impact of LRRK2 kinase activity inhibition on GCase activity, results showed no significant alteration in GCase activity after 24 h inhibition, but LC3-II protein levels were significantly increased. PMC9266636

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice AsPC-1 tumor xenograft model Peritumoral injection 100 mg/kg Three times a week for 4 weeks Inhibited tumor growth, significantly reduced tumor volume and weight PMC4030036
Mice A. fumigatus keratitis model Subconjunctival injection 1 μg/μL or 2 μg/μL Single injection, lasting 24 hours LRRK2-IN-1 significantly mitigated the corneal injury and inflammation caused by A. fumigatus infection, reduced clinical scores and fungal burden, indicating that LRRK2-IN-1 alleviates A. fumigatus keratitis by inhibiting STING-related signaling pathways. PMC11804891
Drosophila melanogaster LRRK2-G2019S mutant Drosophila model Oral feeding 2.5 μM From eclosion until testing LRRK2-IN-1 partially rescued the frequency of PER responses in LRRK2-G2019S mutant flies, from 32% to 47%. PMC5715132
Drosophila Drosophila model expressing LRRK2-G2019S Food administration 2.5 mM From larval stage to adult stage To test the effect of LRRK2-IN-1 on the visual response of Drosophila expressing LRRK2-G2019S, and it was found that it could restore the visual response of the flies to normal levels. PMC4119403
Caenorhabditis elegans Transgenic C. elegans expressing human R1441C- and G2019S-LRRK2 Liquid culture 6.80 µM From L1 to L4 stage, L4 to adult Day 2, and adult Day 2 to Day 3 Prevented and reversed dopaminergic behavioral deficits and neurodegeneration PMC3526163

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.75mL

0.35mL

0.18mL

8.76mL

1.75mL

0.88mL

17.52mL

3.50mL

1.75mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Yao C, Johnson WM, et al. Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity. Hum Mol Genet. 2013 Jan 15;22(2):328-44.

[2]Deng X, Dzamko N, et al. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol. 2011 Apr;7(4):203-5.

[3]Atashrazm F, Dzamko N, et al. LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives. Clin Pharmacol. 2016 Oct 20;8:177-189. eCollection 2016.

[4]Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, Gray NS. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol. 2011 Apr;7(4):203-5. doi: 10.1038/nchembio.538. Epub 2011 Mar 6. PMID: 21378983; PMCID: PMC3287420.

[5]Yao C, Johnson WM, Gao Y, Wang W, Zhang J, Deak M, Alessi DR, Zhu X, Mieyal JJ, Roder H, Wilson-Delfosse AL, Chen SG. Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity. Hum Mol Genet. 2013 Jan 15;22(2):328-44. doi: 10.1093/hmg/dds431. Epub 2012 Oct 12. PMID: 23065705; PMCID: PMC3526163.

[6]Weygant N, Qu D, Berry WL, May R, Chandrakesan P, Owen DB, Sureban SM, Ali N, Janknecht R, Houchen CW. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1. Mol Cancer. 2014 May 6;13:103. doi: 10.1186/1476-4598-13-103. PMID: 24885928; PMCID: PMC4030036.

 

Historical Records

Categories